Skip to content
Empliciti(elotuzumab)
Empliciti (elotuzumab) is an antibody pharmaceutical. Elotuzumab was first approved as Empliciti on 2015-11-30. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. The pharmaceutical is active against SLAM family member 7.
Download report
Favorite
BMS
Case Study: Multiple Myeloma
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Empliciti
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Elotuzumab
Tradename
Proper name
Company
Number
Date
Products
EmplicitielotuzumabBristol-Myers Squibb CompanyN-761035 RX2015-11-30
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
emplicitiBiologic Licensing Application2019-10-28
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
multiple myeloma—D009101C90.0
Agency Specific
FDA
EMA
Expiration
Code
elotuzumab, Empliciti, Bristol-Myers Squibb Company
2025-11-06Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01F: Monoclonal antibodies and antibody drug conjugates
— L01FX: Other monoclonal antibodies and antibody drug conjugates in atc
— L01FX08: Elotuzumab
HCPCS
Code
Description
J9176
Injection, elotuzumab, 1 mg
Clinical
Clinical Trials
61 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101C90.014328—453
LymphomaD008223C85.9——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Smoldering multiple myelomaD000075122—2———2
Plasma cell leukemiaD007952C90.1—1———1
Essential thrombocythemiaD013920D47.3—1———1
Primary myelofibrosisD055728D47.4—1———1
PolycythemiaD011086EFO_0005804D75.1—1———1
Immunoglobulin light-chain amyloidosisD000075363—1———1
Hematologic neoplasmsD019337—1———1
Immunoglobulin g4-related diseaseD000077733—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470C92.01————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameELOTUZUMAB
INNelotuzumab
Description
Elotuzumab (humanized mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID915296-00-3
RxCUI1726104
ChEMBL IDCHEMBL1743010
ChEBI ID—
PubChem CID—
DrugBankDB06317
UNII ID1351PE5UGS (ChemIDplus, GSRS)
Target
Agency Approved
SLAMF7
SLAMF7
Organism
Homo sapiens
Gene name
SLAMF7
Gene synonyms
CS1
NCBI Gene ID
57823
Protein name
SLAM family member 7
Protein synonyms
19A24 protein, CD2 subset 1, CD2-like receptor activating cytotoxic cells, CD2-like receptor-activating cytotoxic cells, CD319, CRACC, Membrane protein FOAP-12, Novel Ly9, novel LY9 (lymphocyte antigen 9) like protein, Protein 19A
Uniprot ID
Q9NQ25
Mouse ortholog
Slamf7 (75345)
SLAM family member 7 (Q8BHK6)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Empliciti - Bristol Myers Squibb
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,786 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
996 adverse events reported
View more details